Company intelligence / Profile preview

Empros Pharma

Solna, Stockholm County, Swedenemprospharma.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Positive topline data from Phase IIb SESAM study showed that a third of patients on EMP16 lost at least 10% of their body weight, with some responders losing up to 23%. The average weight loss was close to 8%. EMP16 demonstrated a well-known safety profile with manageable tolerability. The company plans to begin Phase III trials before the end of 2024, with data expected in 2026[4].

Therapeutic areas: Endocrinology
Modalities: Small molecules (combination therapy)
Industry: Biotech

Drug pipeline

2 assets

EMP16

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Empros Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empros Pharma.